MedTrace Logo

A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects

NCT01612507 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-09-05

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of different dose regimens of Ceftaroline

Conditions

  • Healthy Volunteers

Interventions

DRUG

600 mg Ceftaroline fosamil

1 h infusion

DRUG

Placebo

1 h infusion

DRUG

600 mg Ceftaroline fosamil

2 h infusion

DRUG

Placebo

2 h infusion

Sponsors & Collaborators

Principal Investigators

  • David Melnick, MD · AstraZeneca PharmaceuticalsC2C-7161800 Concord PikePO. Box 15437Wilmington De 19850-5437

  • Elizabeth Tranter, MBCHB MRCP · Hammersmith Medicines Cumberland Avenue London NW10 7EW UK

  • Mirjana Kujacic, MD · AstraZeneca Research and DevelopmentSE-431 83 MolndalSweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612507 on ClinicalTrials.gov